Yüklüyor......
A Food and Drug Administration–Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion
A Food and Drug Administration–approved antiviral agent, known as vidarabine or adenine 9-β-D-arabinofuranoside (AraA), has features of inhibiting adenylyl cyclase type 5 (AC5) and protects against chronic coronary artery occlusion (CAO). The goal of this investigation was to determine whether AraA...
Kaydedildi:
| Yayımlandı: | J Pharmacol Exp Ther |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The American Society for Pharmacology and Experimental Therapeutics
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4851318/ https://ncbi.nlm.nih.gov/pubmed/26941173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.116.232538 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|